Diffuse large B cell lymphoma (DLBL) constitutes the greatest percentage of adult non-Hodgkin's lymphomas and represents a diverse spectrum of lymphoid neoplasms. Clinicopathologic, phenotypic and genotypic findings were correlated and compared for 63 DLBL cases to investigate whether they represent clinically relevant subtypes. They were all cyclin D1 negative and were phenotypically divided into three groups, ie group I (CD5 + type, n = 11), group II (CD5 − CD10 + type, n = 19), and group III (CD5 − CD10 − type, n = 33). Data were correlated by observing the respective gene rearrangement and expression of BCL2 and BCL6. In clinical aspects, the group I cases demonstrated a significantly inferior survival than those of the other two groups (log-rank test, P = 0.016). Although rearrangement of BCL2 and BCL6 did not show any inclination to a specific subgroup, the immunohistochemical detection of BCL2 was less frequent, at a statistically significant level (P = 0.011), in group II (50%) than in group I (82%) and III (82%) cases. This appears to confirm the unique aspect of the CD5 − CD10 + type DLBL, indicating a certain relationship with the normal germinal center cells which usually lack BCL2 expression. The BCL6 protein expression was detected in most of the present DLBL cases (92%) irrespective of this grouping. These data suggest that the phenotypic delineation by the detection of CD5 and CD10 will improve our understanding of DLBL and be helpful in a future subgrouping of DLBL.
Introduction
Diffuse large B cell lymphoma (DLBL) is morphologically characterized by a diffuse proliferation of large lymphoid cells with a nuclear size usually larger than that of tissue macrophages or at least twice the size of small lymphocytes. 1 This entity includes lymphomas defined as centroblastic or immunoblastic in the Kiel classification 2 and large cell immunoblastic or diffuse mixed in the Working Formulation. 3 In the REAL and coming WHO classifications, they are placed in a single category due to the poor reproducibility of attempts to subtype them. This lymphoma may thus be regarded as a heterogeneous category that includes cases arising de novo or by transformation from low-grade B cell lymphomas, and, indeed, it exhibits divergent biologic behavior. Approximately 40% of this type has extranodal presentation, 1 which suggests a certain relationship with mucosa-associated lymphoid tissue (MALT) lymphoma.
To our knowledge, no correlation has been reported in the literature between immunophenotypes and histologic subtypes of large B cell lymphoma (immunophenotypic and genotypic parameters were found not to be helpful for delineating distinctive morphologic subgroups). DLBL accounts for the greatest percentage (48%) of adult non-Hodgkin's lymphoma (NHL) among Japanese patients 4 and for about 40% of initial NHL diagnoses in the United States. 5 Among DLBL, only a few entities, eg primary mediastinal large B cell lymphoma characterized by the fact that it has a peculiar disease site and affects young women, are currently regarded as distinct clinicopathologic diseases 1 although they are not defined in terms of detailed phenotypic and genotypic findings. It is thus essential for a further understanding of DLBL to create reproducible criteria in order to delineate their distinct subtypes, which should be relevant for future therapy strategies.
Cytogenetic studies and molecular analysis of protooncogenes and tumor suppressor genes have provided insights into the pathogenesis of non-Hodgkin's lymphoma. They are also relevant for diagnosis and establishment of prognosis. Therefore, much interest has recently been focused on the pathobiologic significance of BCL1, BCL2 and BCL6 genes in B cell neoplasms. Rearrangement of the BCL2 gene on chromosome band 18q21 has been observed in up to 85% of follicular lymphomas (FL), [6] [7] [8] while rearrangement of the BCL1 gene on chromosome band 11q13 was detected in mantle cell lymphoma (MCL) with anti-cyclin D1 monoclonal antibody. [9] [10] [11] [12] Although no single genetic abnormality has been consistently associated with DLBL, rearrangement of BCL2 has been reported to occur in 20-30% of patients and to correlate with a reduction in overall or disease-free survival. 13, 14 The BCL6 gene, located on chromosome 3q27, encodes for a zinc-finger protein sharing homology with several transcription factors that participate in the control of cell proliferation, differentiation and organ formation. [15] [16] [17] Clonal BCL6 gene rearrangement appears to be associated with lymphomagenesis. [15] [16] [17] [18] [19] [20] [21] DNA analysis has identified the frequency of BCL6 rearrangement as 14-20% of NHL cases, and 27-45% of diffuse large cell type lymphoma cases. [20] [21] [22] Immunophenotyping is most relevant for defining the lymphocyte subsets, and subsequently the putative normal counterpart of each type of lymphoid neoplasm. Among the B cell lymphomas, CD5 is nearly always expressed in cases of MCL, but rarely in cases of FL, and vice versa for the expression of CD10. CD5
+ CD10 − and CD5 − CD10 + phenotypes are often encountered in DLBL tumors, but their phenotypic link to respectively mantle zone cells and germinal center cells remains to be clarified.
For this study, 63 DLBL cases were immunophenotypically divided into three groups of CD5
, and CD5 − CD10 − type, all of which have been confirmed to be cyclin D1 negative. We attempted to correlate their clinicopathologic features and phenotype with molecular data of BCL2 and BCL6 based on the Southern blot and immunohistochemical analyses. Findings from such a study may lead to a better understanding of the nature of DLBL lesions, because results from previously published genotypic studies of these tumors have not been analyzed in relation to the immunophenotypes of lymphoma cells.
Materials and methods

Patients
Samples of lymph node or other tumors from 63 patients with DLBL were collected at the Aichi Cancer Center Hospital and affiliated hospitals. They were selected from 246 consecutive DLBL cases diagnosed at the Department of Pathology and Clinical Laboratories, Aichi Cancer Center Hospital, between October 1985 and November 1996. The pathologic diagnoses were established by three independent hematopathologists (YY, TS and SN) according to the updated Kiel classification and the REAL classification. Patients without an available sample for DNA or phenotypic analyses were excluded from this study. The cases with previous or simultaneous low-grade lymphomas, as well as those diagnosed as specific subtypes, eg mediastinal B cell lymphoma or pyothorax-associated lymphoma were excluded.
Combined chemotherapeutic regimens containing doxorubicin (ie cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); vincristine, cyclophosphamide, prednisolone and doxorubicin (VEPA); or VEPA and methotrexate) were used as the standard treatment for patients with DLBL in advanced stages (stages II-IV). 23, 24 Patients with stage I lymphoma were treated with either radiotherapy only or with a combination of radiation and chemotherapy.
We categorized DLBL cases on the basis of the presence or absence of the representative surface markers (CD5 and CD10) examined by flowcytometry: group I (CD5 
Light microscopy
Tissue samples were fixed in 10% formalin and embedded in paraffin. Sections (5-mm thick) were stained with hematoxylin and eosin, Elastica-van Gieson, silver impregnation, periodic acid-Schiff, May-Grü nwald-Giemsa, and methyl green-pyronine. Imprint smears of the surgically resected specimens were stained with May-Grü nwald-Giemsa.
Immunohistochemistry and flowcytometry
The surface markers of the tumor cells of each case were analyzed as described previously. 10, 12 In brief, immunoperoxidase studies were performed on formalin-fixed paraffin sections by using an avidin-biotin peroxidase complex (ABC) method. A panel of monoclonal antibodies consisting of CD3, UCHL-1/CD45RO, L26/CD20, Ber-H2/CD30, CD79a (Dako, Copenhagen, Denmark) and MT1/CD43 (Bioscience Products, Emmenbrü ke, Switzerland) was used. Tumors were considered to be of B cell origin when the neoplastic cells expressed CD20 or CD79a and lacked T cell-associated markers (CD3, CD43, and/or CD45RO). A T cell lineage was assigned if the opposite pattern of reactivity was observed.
Immunohistochemistry on paraffin sections of PRAD1/cyclin D1 (5D4 11 ), BCL2 (Dako), and BCL6 (Novocastra Laboratories, Newcastle, UK) was also performed with the ABC method. Lymphoma cell positivity of more than 10% was adopted as the standard of positivity for these oncogene products.
Surface immunophenotyping of the lymphoma cells was also performed with the aid of flowcytometry using the following panel of lymphoid-associated monoclonal antibodies: OKT6 (CD1), OKT11 (CD2), OKT3 (CD3), OKT4 (CD4), OKT8 (CD8), OKIa 1 (Ortho, Raritan, NJ, USA), J5 (CD10) (Coulter, Hialeah, FL, USA), Leu5 (CD2), Leu4 (CD3), Leu3a (CD4), Leu1 (CD5), Leu2 (CD8), Leu11 (CD16), Leu7 (CD57), (Becton Dickinson, Mountain View, CA, USA), B1 (CD20), B2 (CD21), B4 (CD19) and NKH1 (CD56) (DAKO). Multiparameter analysis of gated cell populations during cell suspension studies was used to provide more definitive immunophenotypic information (Consort 30 computer software; Becton Dickinson).
DNA extraction and Southern blot analysis
Genomic DNA was extracted from the tumor samples as described previously. 25 Briefly, frozen tumor samples were resuspended in 9.5 ml of lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM EDTA, 150 mM NaCl, 0.4% sodium dodecyl sulfate (SDS) and 500 l of 20 mg/ml proteinase K). After overnight incubation at 37°C, the mixture was extracted twice with phenol/chloroform and the aqueous phase was precipitated with 2.5 volume of ethanol. The precipitate was then washed twice in 70% ethanol. The genomic DNA obtained was dried and dissolved in TE buffer (10 mM Tris-HCl pH 7.4, 1 mM EDTA pH 8.0). For Southern blot analysis, 10 g of DNA was digested with the appropriate restriction enzyme, electrophoresed on 0.7% agarose gel, and transferred to nylon membranes (Hybond N, Amersham-Japan, Tokyo, Japan). Probes were radiolabeled by using a random primer DNA labeling kit (Nippon Gene, Toyama, Japan) with [␣-32 P] dCTP. After overnight hybridization, filters were washed to a final stringency of 0.1 × standard saline citrate (SSC)/0.1% SDS at 60°C and then autoradiographed using intensifying screens.
DNA probes
The BCL2 probes used have been described elsewhere. 7 These included the 1.2-kilobase (kb) SacI fragment which recognizes 5ЈBCL2, the 2.8-kb EcoRI-HindIII fragment of the mbr (major breakpoint cluster region) and the 4.0-kb EcoRI fragment of the mcr (minor breakpoint cluster region). The restriction enzymes used for the BCL2 gene analysis were EcoRI, HindIII and BamHI.
The BCL6 gene was analyzed by hybrydization of BamHI and XbaI-digested DNA to the human BCL6 probe Sac 4.0. 17 In selected cases, a second probe representative of the BCL6 locus, Sac 0.8, was also used (kindly provided by Dr R Dalla-Favera, College of Physicians and Surgeons, Columbia University, New York, NY, USA).
Statistical analysis
Overall survival was calculated from the date of diagnosis until the patients' death or last follow-up. Survival curves were plotted with the method of Kaplan and Meier 26 and were compared with the log-rank test.
groupings and initial clinical features and gene alterations were analyzed with the two-sided chi-squared test.
Results
Patients' characteristics
The clinical features of the 63 cases are summarized in Table 1 . There were 31 men and 32 women with a median age of 57 years at diagnosis (range, 21-89 years). The disease was in advanced stages (III or IV) at diagnosis in 39 (62%) of the patients and in an early clinical stage (stage I or II) in 24 (38%). In most cases, the lymphoadenopathy was superficial, but 30 patients (48%) presented with extranodal lesions as the major sites of disease at diagnosis (Table 1 ). These extranodal lesions included one in the arm, six in the breast, five in the colon, two in the nasal cavity, one on the skin, one in the soft tissue, one in the subcutis, two in the spleen, five in the stomach, one in the testis, one in the thyroid and four in the tonsil. An enzyme-linked immunosorbent assay of the serum obtained from all patients did not reveal any antibodies to human T cell leukemia/lymphoma virus type 1, nor did an analysis of their life styles suggest any risk factors for acquired immunodeficiency disease. None of the cases showed occurrence of a second neoplasm during their entire clinical course.
Twenty-two of the 63 patients were alive at the last followup, with a median follow-up time of 47 months from the diagnosis of DLBL. Fifty-two (83%) of the 63 patients achieved complete response with conventional chemotherapy, although 31 of them relapsed 1-74 months after the time of diagnosis.
Immunohistochemical analysis of cyclin D1
In several previous reports, including one of ours, 11 nuclear positive immunostaining of cyclin D1 has been shown to reflect cyclin D1 mRNA overexpression and to be relevant for the diagnosis of MCL. Based on this observation, all of the present cases were examined by cyclin D1 immunohistochemistry and were found to be completely negative (Table 1) .
Gene rearrangement and immunohistochemical analysis of BCL2
BCL2 gene rearrangement was detected in six out of 63 (10%) cases: in group I (1/11, 9%), group II (1/19, 5%) and group III (4/33, 12%). The mbr probe demonstrated rearrangement in five of them, the 5Ј BCL2 probe in one and the mcr probe in none ( Table 1 ). The frequency of BCL2 gene rearrangement in DLBL was similar to that reported in a previous study of ours. 8 The BCL2 protein expression was also immunohistochemically identified in 45 out of 62 (73%) cases: in group I (9/11, 82%), group II (9/18, 50%) and group III (27/33, 82%). All of the six cases with BCL2 rearrangements also demonstrated strong expression of the BCL2 protein (Figure 1a) . However, among the BCL2-positive cases, there was no significant difference in the strength of BCL2 expression between the cases with and without BCL2 rearrangements.
Gene rearrangement and immunohistochemical analysis of BCL6
Rearranged BCL6 was found in 16 out of 63 (25%) cases: in group I (2/11, 18%), group II (3/19, 16%) and group III (11/33, 33%), but this relatively high incidence in group III was not statistically significant (Table 1) . Furthermore, in the group III cases, eight of the 18 (44%) DLBLs occurring in the extranodal sites showed alteration of the BCL6 gene. The frequency was relatively higher than that (3/15, 20%) of those in nodal sites, but the difference was not statistically significant. The anatomical sites of the extranodal lesions with BCL6 rearrangement were the stomach (three of four, 75%), the tonsil (two of three, 67%), the colon (one of three, 33%), the breast (one of five, 20%), and other (one of three, 33%).
Immunohistochemical examination of the BCL6 protein showed a positive reaction in 57 cases (92%): 10 out of 11 (91%) in group I, 17 out of 18 (94%) in group II and 30 out of 33 (91%) in group III (Figure 1c ). Only one case (No. 8) stained negatively for BCL6 in spite of the rearrangement of BCL6 (Table 1) .
Correlation among the clinical, phenotypic, genetic and immunohistochemical findings
Clinical, phenotypic, genetic and immunohistochemical features of these 63 patients are summarized in Table 2 . The Kaplan-Meier survival curves for the three groups of DLBL divided by phenotype are shown in Figure 2 . The overall survival of group I was significantly inferior to those of groups II and III (P = 0.016 by log-rank test), while the latter two groups showed identical survival. When the overall survival of group I was compared with the mixed group of groups II and III, ie CD5
+ vs CD5 − groups, the survival of group I becomes more significant (P = 0.004 by log-rank test, data not shown). The group I cases were also characterized by a high incidence of bone marrow involvement, which was significant in terms of the 2 × 3 chi-square test for independence (4/11, P = 0.045) and of the chi-square test (P = 0.041) in comparison with the other two groups.
The prognoses of the present cases did not correlate with the genetic or immunohistochemical data obtained in this study. However, a lower incidence of BCL2 expression in group II was demonstrated to be significant according to the 2 × 3 chi-square test for independence (P = 0.039) and the chisquare test in comparison with the other two groups (P = 0.011).
In order to compare our present data with those previously published, all cases were statistically analyzed as a whole regardless of phenotype. None of the various clinical features including age, sex, clinical stage, histologic subtype (immunoblastic or not), site of origin (nodal or extranodal), bone marrow involvement, and complete response (data not shown) correlated significantly with either BCL2 or BCL6 rearrangements. The complete response rate in BCL6 immunostaining-negative cases was found to be significantly less than that in BCL6-positive cases (P = 0.019, chi-square test), although the number of BCL6-negative cases was small.
Discussion
Lymphoma classification based on morphology and cytologic composition alone is not necessarily suitable because com- pletely different biologic entities can have relatively similar appearances. Therefore, definition of disease entity has to be based on a combination of clinical, histologic, phenotypic and genotypic features. In practice, the representative types of low-grade B cell tumors have been phenotypically and genotypically defined in addition to an analysis of their morphologic features:
1 MCL has a CD5 + phenotype and has cyclin D1 overexpression activated by t (11;14) ; FL has a CD5 − CD10
+ phenotype with abnormal expression of BCL2 by t(14;18); and marginal zone B cell lymphoma of MALT type has a CD5 − CD10 − phenotype often with t(11;18) or trisomy 3 which remains to be genetically clarified. Until now, however, the attempts to delineate a specific group among DLBL cases on genetic and phenotypic grounds have resulted in failure 1 although a few distinct subtypes, eg mediastinal large cell Table 2 Clinicopathologic characteristics, BCL2 and BCL6 analyses by immunophenotypic subgroup Group I Group II Group III P value (n = 11) (n = 19) (n = 33) 
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Overall survival of patients (Kaplan-Meier method) in groups I, II and III. lymphoma and intravascular lymphomatosis, have been defined in terms of their peculiar clinicopathologic features. Previous studies have reported the detection of BCL1 and BCL2 rearrangements in a small percentage of DLBL cases. BCL6 rearrangements have also been reported as one of the most frequent gene alterations in DLBLs. 28 Patients with BCL6 genetic alterations were subsequently described to have a better clinical outcome, 19 but this has been contradicted by other studies. 20, 29 All clinical characteristics were also evenly distributed between patients with rearranged and those with germ-line BCL6 in such studies. 20, 29 Thus, it is still controversial whether the BCL6 gene can be a useful marker for defining a subset of DLBLs. In an attempt to establish definite dividing lines among DLBL cases, three groups have been identified in the present study on the basis of their surface markers: group I (CD5 + CD10 − CD20 + type), group II (CD5 − CD10 + CD20 + type), and group III (CD5 − CD10 − CD20 + type). This grouping is based on the hypothesis that the expression of CD5 and CD10 may be related to developmental stages of mantle zone cell and follicular center cell, or certain subsets of B cell neoplasms, ie MCL and FL. To our knowledge, this is the first report of a correlative analysis of clinical, phenotypic, genotypic and immunohistochemical findings for DLBL cases.
The present study highlights the clinical significance of identifying the CD5 phenotype of DLBLs. The group I cases of this phenotype were characterized by a more aggressive clinical course and more frequent bone marrow involvement than those in groups II and III. All cases were cyclin D1 negative, and most expressed the BCL2 and BCL6 proteins, although only a few cases showed their genetic alterations. They were also distinct from other CD5 + low-grade tumors, that is, MCL and CLL, in that they showed a high frequency of somatic mutations in the heavy chain variable region of the immunoglobulin gene as described by us and others. 30, 31 The number of the group I cases appears to be relatively small, which may represent the incidence of this phenotype in DLBL. The clinical significance of CD5 + phenotype in DLBL should be confirmed in a larger number of the cases examined. As well, further investigation is needed for clarifying the putative normal counterpart of this group.
There were no significant differences in clinical features and overall survival between groups II and III. However, the incidence of BCL2 expression in group II (50%, Figure 1b) 32 while an alternative explanation is that they might have originated from the other normal counterparts which were BCL2 + . Monni et al 34 also suggested the possibility that BCL2 expression is caused by gene amplification at follicular center cell stage B cells, which can hardly be detected by Southern blot analysis. A method such as fluorescence in situ hybridization, which can cover much larger regions, may also be useful for examining whether these cases feature BCL2 translocation. Although the present study failed to show clinical relevance for the group in question, a less positive BCL2 expression might be an important feature for future therapy strategies aiming at apoptosis. The CD5 − CD10 − phenotype was most frequently observed among the DLBL cases. In the present study, group III of this phenotype demonstrated a higher incidence of BCL6 gene rearrangement as compared to the other two groups although the difference was not significant. Interestingly, the cases which occurred in the extranodal sites, especially those in the stomach, had a greater percentage of BCL6 gene rearrangements, suggesting that these genetic alterations are related to the particular anatomical site of the tumor. Further analyses, including molecular dissection other than of BCL1/cyclin D1, BCL2 and BCL6 are therefore called for.
Survival was analyzed for the total population of the present series by correlating them with BCL2 and BCL6 and their gene rearrangements, as has been advocated by several groups. [18] [19] [20] [21] [22] 29, 35, 36 The positive BCL2 immunostaining has been reported to be associated with a poor prognosis in DLBL cases although BCL2 gene rearrangement did not show any such significance. 36 Our data indicated, however, that both BCL2 positivity and BCL2 gene rearrangement show no prognostic significance. The BCL6 gene rearrangement also showed no significant relationship with survival, which was in keeping with the other investigations, while a immunohistochemical negativity of BCL6 was associated with a poor prognosis (P = 0.004). This should be confirmed in a larger-scale study since the number of BCL6 unstained cases was limited in the present study.
It is noteworthy that case No. 8 showed BCL6 gene rearrangement in spite of less than 10% BCL6-positive tumor cells. This case simultaneously showed more than 90% positivity in BCL2 staining, suggesting that the reduced expression of BCL6 may not be affected by prolonged formal in fixation. Indeed, the relation between BCL6 immunostaining and gene rearrangement is currently not well clarified. It has been indicated that activation of the BCL6 gene is essential for B cells to give rise to germinal center formation 37 and the BCL6 protein has been immunohistochemically detected in germinal center B cells. 38 Thus, it is possible that the positive staining of BCL6 without BCL6 gene rearrangement may indicate the origin of DLBL to be follicular center cells. Further studies are required to clarify the relationship of BCL6 protein expression with normally regulated and deregulated expression resulting from BCL6 gene rearrangement.
Our present study shows the importance of surface phenotyping of CD5 and CD10 with reference to the expression of oncogenes and clinical outcomes. Further investigations with other phenotypic or molecular markers are warranted for new insights into the development of malignant lymphomas and to help establish more effective therapeutic strategies.
